Pomalidomide: Pharmac is funding the brand Pomolide

From 1 August, Pomalidomide is funded to treat plasma cell dyscrasias. These are conditions where a type of white blood cell makes too many copies of itself or secretes abnormal proteins into the bloodstream.

30 July 2024 | Update

Information for pharmacies on process for ordering Pomolide updated.

When will the medicine will be available?

From 1 August 2024, Pomolide will be funded for people with plasma cell dyscrasia that has come back (relapsed) or has stopped responding to other treatments (refactory). It will be supplied by Juno Pharmaceuticals.

Full details of the access criteria are available in our funding announcement for pomalidomide.

For prescribers and pharmacists

Health care professionals prescribing and dispensing Pomolide will need to register with the Pomolide pregnancy prevention program where prescribing and dispensing will be recorded.

Juno Connected

Downloadable/printable information resources for health care professional and patients are available for health care professional to access once signed up to the risk management programme.

For pharmacies

Any pharmacy that has an agreement to provide community pharmacy services can dispense and claim for pomalidomide. Pharmacies do not need a specific agreement to dispense pomalidomide.

Ordering Pomolide 

Healthcare Logistics (HCL) is the only supplier of Pomolide for pharmacies. It is available to order.

Before you can order Pomolide from HCL, your pharmacy must be registered with Juno Connected(external link). Juno has created a process flow chart to help.

Ordering process for Pomolide (pomolidomide) – Juno [PDF, 526 KB]

Who to contact

If you have any questions about accessing this treatment, talk to a health care professional you trust. 

Any questions about signing up to Juno Connected contact Juno Connected Customer Care line: 0800 857 030 

If you have questions about funding or access criteria: